An Open-Label Investigation of the Effects of Sub-Perceptual Repeat Dosing of Psilocybin on the Behavioural and Cognitive Symptoms of Fragile X Syndrome in Adult Patients
Latest Information Update: 14 May 2024
At a glance
- Drugs Psilocybin (Primary)
- Indications Fragile X syndrome; Pervasive child development disorders
- Focus Therapeutic Use
- Sponsors Nova Mentis Life Science
- 06 May 2024 Planned End Date changed from 1 Apr 2024 to 1 May 2024.
- 06 May 2024 Planned primary completion date changed from 1 Apr 2024 to 1 May 2024.
- 06 May 2024 Status changed from recruiting to suspended. (Indefinite hold due to protocol revisions relating to the exclusion criteria for concurrent medications.)